Riskpilot← Back to searchSign inGet full accessNova MedicArt AB
ABBankruptOrg 5590033071Beauty care and other beauty treatment activities · NACE 9622Est. 20150 employees
Revenue 2023
SEK 424K
-71% vs 2022
EBITDA margin
59.4%
+345% vs 2022
Equity ratio
10.2%
Financial strength
Net profit 2023
SEK 221K
+314% vs 2022
| Revenue | SEK 424K | -71% |
| EBITDA | SEK 252K | +345% |
| Net profit | SEK 221K | +314% |
| Total assets | SEK 920K | +42% |
| Equity | SEK 94K | -85% |
| Employees | 0 | — |
Legal name
Nova MedicArt AB
Org number
5590033071
Legal form
Aktiebolag
NACE code
9622 · Beauty care and other beauty treatment activities
Founded
9 februari 2015
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolagets ändamål är att bedriva specialistläkarverksamhet inom öppenvård (ej på sjukhus), tandläkarverksamhet, skönhetsvård, hårvård, ekonomisk förvaltning samt därmed förenlig verksamhet.
Address
Email
sadr.mirhosseni@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 620 | 1 440 | 3 673 | 1 481 | 424 |
| Staff expenses | — | — | — | −431 | −408 |
| EBITDA | 71 | −881 | 1 167 | −103 | 252 |
| Depreciation & amort. | −0 | −0 | −33 | — | — |
| EBIT | 71 | −881 | 1 134 | −103 | 252 |
| Net financials | — | −1 | −1 | — | −1 |
| Profit before tax | 71 | −882 | 1 133 | −103 | 251 |
| Tax | −0 | −0 | −0 | — | −31 |
| Net profit | 71 | −882 | 1 133 | −103 | 221 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 1 042 | 523 | 914 | 647 | 920 |
| Equity | 595 | 343 | 726 | 624 | 94 |
| Long-term debt | 0 | 0 | 0 | — | 744 |
| Short-term debt | 447 | 180 | 187 | 23 | 82 |
| Total debt | 447 | 180 | 187 | 23 | 826 |
EBITDA margin
59.4%
This company
15.8%
Market median
+276% vs market
20192023
Equity ratio
10.2%
This company
38.2%
Market median
-73% vs market
20192023
Return on equity
234.4%
This company
18.4%
Market median
+1174% vs market
20192023
Net profit margin
52.0%
This company
8.1%
Market median
+542% vs market
20192023
Asset turnover
0.46×
This company
1.12×
Market median
-59% vs market
20192023
Debt / equity
8.78×
This company
0.62×
Market median
-1316% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2024 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Nova MedicArt AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rex Lincoln Christian K Montroyal | Deputy Board Member | 0 companies |
| Sayed Ziaedin Mirhosseni | Board of Directors | 0 companies |
| Sayed Sadreddin Mir Hosseini Renani | Deputy Board Member | 0 companies |